July 2022

Updated NCCN Breast Cancer Clinical Practice Guidelines
The National Comprehensive Care Network (NCCN) recently updated its breast cancer (BC) clinical practice guidelines. These guidelines and their accompanying algorithms are widely used in the management of the oncology patient. Pharmacists should be aware of these latest recommendations in order to optimize the care of their patients with BC. Learn more about these guidelines.


Evidence on the Management of TNBC in Older Women
Triple-negative breast cancer (TNBC) is associated with poor outcome. Treatment is limited to the use of chemotherapy to reduce the risk of recurrence. However, there are no large, randomized studies on the use of this therapeutic modality in older women with early TNBC. Recent guidelines indicate that data are too limited to make recommendations on the use of adjuvant chemotherapy. Read more.

Hemorrhage Risk Among BC Patients Receiving Tamoxifen, DOACs
Breast cancer (BC) is associated with an increased annual venous thromboembolic risk of 2% to 6% and a twofold elevated risk of atrial fibrillation. Tamoxifen has a boxed warning about the risk of serious life-threatening and fatal events. Learn more about a recent study that offers pharmacists encouraging evidence of the potential safety of tamoxifen/direct oral-acting anticoagulant (DOAC) co-administration.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App